Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling
- 327 Downloads
Mutations in the PIK3CA gene are common in breast cancer and represent a clinically useful therapeutic target. Several larger, population-based studies have shown a positive prognostic significance associated with these mutations. This study aims to further identify characteristics of patients harboring PIK3CA mutations while evaluating the clinical impact of genomic testing for these mutations. Tumors from 312 patients at Vanderbilt-Ingram Cancer Center were analyzed for PIK3CA mutations using a multiplex screening assay (SNaPshot). Mutation rates, receptor status, histopathologic characteristics, and time to recurrence were assessed. The number of patients participating in clinical trials, specifically trials relating to the PIK3CA mutation, was examined. Statistically significant differences between wild-type and mutated tumors were determined using the Wilcoxon, Pearson, and Fischer exact tests. The PIK3CA mutation was found in 25 % of tumors tested. Patients with PIK3CA mutations were significantly more likely to express hormone receptors, be of lower combined histological grade, and have a reduced time to recurrence. Patients found to have a PIK3CA mutation were significantly more likely to enter a PIK3CA-specific clinical trial. In addition to confirming previously established positive prognostic characteristics of tumors harboring PIK3CA mutations, this study demonstrates the feasibility and utility of mutation profiling in a clinical setting. PIK3CA mutation testing impacted treatment and resulted in more patients entering mutation-specific clinical trials.
KeywordsPIK3CA mutation PI3K Breast cancer SNaPshot
This study was supported by Grant UL1 TR000445 from NCATS/NIH. The support of Ms. Jamie Farley in consenting patients for this study is acknowledged.
Conflict of interest
The authors declare that they have no conflict of interest.
The experiments in this manuscript comply with the current laws of the United States.
- 12.Gonzalez-Angulo AM et al (2013) Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7–15PubMedCentralPubMedCrossRefGoogle Scholar
- 23.Baselga, J., et al.,: Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). In: Thirty-fifth annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, 4–8 Dec 2012; Cancer. Res. 72(24 Supplement), S5–1 (2012)Google Scholar
- 24.Baselga J, M.I., Nuciforo PG et al. (2013) PI3KCA mutations and correlation with pCR in the NeoALTTO trial (BIG 01-06). Presented at European Cancer Congress 2013; Sep 27–Oct 1,2013 ; Amsterdam. Abstract 1859, 2013Google Scholar